Richard Nicholas

Summary

Affiliation: Imperial College Healthcare NHS Trust
Country: UK

Publications

  1. pmc Innate immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1)
    Pascal F Durrenberger
    Department of Medicine, Section of Infectious Diseases and Immunity, Commonwealth Building, Hammersmith Campus, Imperial College London, UK
    J Neuroinflammation 9:1. 2012
  2. pmc Development of oral immunomodulatory agents in the management of multiple sclerosis
    Richard Nicholas
    Imperial College Healthcare NHS Trust, London, UK
    Drug Des Devel Ther 5:255-74. 2011
  3. ncbi request reprint Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis
    Richard Nicholas
    Imperial College Healthcare NHS Trust, London, UK
    Mult Scler 18:1290-6. 2012
  4. doi request reprint Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design
    Richard Nicholas
    Imperial College Healthcare NHS Trust, London, UK
    Mult Scler 17:1211-7. 2011
  5. ncbi request reprint Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
    Jeremy Chataway
    National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK UCL Institute of Neurology, University College London, London, UK Imperial College Healthcare NHS Trust, London, UK Imperial College, London, UK Electronic address
    Lancet 383:2213-21. 2014
  6. doi request reprint Bladder symptoms in multiple sclerosis: a review of pathophysiology and management
    Richard Nicholas
    Imperial College Healthcare NHS Trust, Charing Cross Hospital, Department of Neurosciences, London, UK
    Expert Opin Drug Saf 9:905-15. 2010
  7. doi request reprint A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis
    Jeremy Chataway
    National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London, UK
    Mult Scler 17:81-8. 2011

Collaborators

Detail Information

Publications7

  1. pmc Innate immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1)
    Pascal F Durrenberger
    Department of Medicine, Section of Infectious Diseases and Immunity, Commonwealth Building, Hammersmith Campus, Imperial College London, UK
    J Neuroinflammation 9:1. 2012
    ..In this study, we investigated whether there were differences in NCR1+ cells in the peripheral blood of MS patients and whether NCR1+ cells are present in white matter lesions...
  2. pmc Development of oral immunomodulatory agents in the management of multiple sclerosis
    Richard Nicholas
    Imperial College Healthcare NHS Trust, London, UK
    Drug Des Devel Ther 5:255-74. 2011
    ....
  3. ncbi request reprint Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis
    Richard Nicholas
    Imperial College Healthcare NHS Trust, London, UK
    Mult Scler 18:1290-6. 2012
    ..Although it is known that the annualized relapse rate (ARR) in patients with multiple sclerosis (MS) changes as disease progresses, in the design and analysis of trials in relapsing multiple sclerosis (RMS) constant ARRs are assumed...
  4. doi request reprint Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design
    Richard Nicholas
    Imperial College Healthcare NHS Trust, London, UK
    Mult Scler 17:1211-7. 2011
    ..Planning a randomized placebo-controlled trial in relapsing-remitting multiple sclerosis (RRMS) requires knowledge of the annualized relapse rate (ARR) in the placebo group...
  5. ncbi request reprint Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
    Jeremy Chataway
    National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK UCL Institute of Neurology, University College London, London, UK Imperial College Healthcare NHS Trust, London, UK Imperial College, London, UK Electronic address
    Lancet 383:2213-21. 2014
    ....
  6. doi request reprint Bladder symptoms in multiple sclerosis: a review of pathophysiology and management
    Richard Nicholas
    Imperial College Healthcare NHS Trust, Charing Cross Hospital, Department of Neurosciences, London, UK
    Expert Opin Drug Saf 9:905-15. 2010
    ....
  7. doi request reprint A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis
    Jeremy Chataway
    National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London, UK
    Mult Scler 17:81-8. 2011
    ....